ArticleEuropean journal of nuclear medicine and molecular imaging2007
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.
Article in European journal of nuclear medicine and molecular imaging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [18F]FDG PET/CT versus [18F]FDG PET/MRI for the diagnosis of colorectal liver metastasis: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.The Cochrane database of systematic reviews · 2019Pooled it
- Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.Journal of the National Cancer Institute · 2011Pooled it
- Evaluation of PET/CT in patients with stage III malignant cutaneous melanoma.American journal of nuclear medicine and molecular imaging · 2019Article
- Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction.European journal of nuclear medicine and molecular imaging · 2018Article
- Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.Journal for immunotherapy of cancer · 2016Article
- Article
- Rectal adenocarcinoma metastatic to the tonsil; PET-CT observations with pathological confirmation: A case report.Oncology letters · 2014Article
- Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.Yonsei medical journal · 2013Article
- Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.Insights into imaging · 2013Article
- Blind spots at oncological CT: lessons learned from PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Review
- PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.European journal of nuclear medicine and molecular imaging · 2011Article
- Article
- Radiography, Bone Scan, and F-18 FDG PET/CT Imaging Findings in a Patient with Paget's Disease.Nuclear medicine and molecular imaging · 2010Article
- PET/CT in oncology: for which tumours is it the reference standard?Cancer imaging : the official publication of the International Cancer Imaging Society · 2007Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this retrospective, blinded study was to evaluate the additional value of [18F]FDG PET/CT in comparison with PET alone and with side-by-side PET and CT in patients with malignant melanoma (MM).
methodsA total of 127 consecutive studies of patients with known MM referred for a whole-body PET/CT examination were included in this study. PET alone, side-by-side PET and CT and integrated PET/CT study were independently and separately interpreted without awareness of the clinical information. One score each was applied for certainty of lesion localisation and for certainty of lesion characterisation. Verification of the findings was subsequently performed using all available clinical, pathological (n=30) and follow-up information.
resultsThe number of lesions with an uncertain localisation was significantly (p<0.001) reduced by PET/CT and side-by-side PET and CT (p<0.05) in comparison with PET alone. In line with this increase in certainty integrated PET/CT reading also improved certainty in characterisation of lesions, however, this did not reach significance (p=0.057) compared versus PET alone. Respectively, PET, side-by-side PET and CT and PET/CT showed a sensitivity of 86%, 89% and 91%, a specificity of 94%, 94% and 94%, a positive predictive value of 96%, 96% and 96% and a negative predictive value of 80%, 83% and 87%.
conclusionIntegrated PET/CT offers a significant benefit in lesion localisation and an improvement in lesion characterisation compared with PET alone or with side-by-side PET and CT. The benefit is not as great as that reported for other tumour entities, which may be due to the high avidity of MM for [18F]FDG.
Indexed as
Identifiers
17295038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.